Last Updated:

Covaxin Found Neutralising COVID-19 Beta & Delta Variants, Says ICMR Study

An ICMR study on Monday, has established that Bharat Biotech's Covaxin is effective in neutralising both COVID variants -B.1.351 (Beta) and B.1.617.2 (Delta)

Covaxin, COVID variant

IMAGE: PTI


As India's vaccination drive picks up, an ICMR study on Monday, has established that Bharat Biotech's Covaxin is effective in neutralising both COVID variants -B.1.351 (Beta) and B.1.617.2 (Delta).  The study titled 'Neutralization against B.1.351 and B.1.617.2 with sera of COVID-19 recovered cases and vaccinees of BBV152'  has been conducted on a small set of subjects - 20 COVID recovered subjects & 17 Covaxin-inoculated individuals. The study, authored by Dr. Pragya D Yadav from the National Institute of Virology, is not peer-reviewed yet and has been uploaded to Biorxiv's pre-print server on Monday. 

Covaxin neutralises Beta & Delta variant: ICMR study

The study was performed 5-20 weeks after infection on 20 individuals who had recovered COVID-19 and on 17 subjects who have who received both doses of Covaxin, 28 days after the jabs. The study observed the neutralisation potential of Covaxin on the two variants Beta and Delta compared to the regular COVID-19 virus B.1 (D614G). The study demonstrated that while Covaxin's neutralisation capacity is reduced against the two variants, the potential is well established. Lastly, the broad epitope coverage of Covaxin decreases the magnitude of reduced neutralization against emerging variants. 

"We observed a reduction in neutralization titers with sera of COVID-19 recovered cases and BBV152 vaccines against B.1.351 and B.1.617.2 respectively. Our study demonstrated that despite a reduction in neutralization titers with BBV152 vaccinees sera against B.1.351 and B.1.617.2, its neutralization potential is well established. Lastly, the broad epitope coverage of an inactivated vaccine (BBV152)," concluded the study.

Covishield produces more antibodies than Covaxin

This study comes days after another interim study by 7 top Indian doctors revealed that Covishield has produced higher antibodies (seropositivity) than Covaxin in its test subjects. The study headed by G.D Hospital & Diabetes Institute's Dr. A. K. Singh from Kolkata, which is yet to be published and peer-reviewed, states that of the 515 Healthcare workers 95.0% showed seropositivity after two doses of both vaccines. The study also stated that the effects of the vaccines were similar irrespective of sex, BMI, blood group, and any comorbidities except Type-2 diabetes in recipients above 60 years.

The study which was conducted on 515 Healthcare workers had 425 Covishield recipients who displayed a  98.1% seropositivity and  90 Covaxin recipients who had 80.0% seropositivity. The 95% seropositivity observed overall was 21-36 days after the second completed dose. The study was a pan-India cross-sectional Coronavirus Vaccine-induced Antibody Titre (COVAT) research conducted on recipients 21 days after they received their second dose. The recipients comprised of those who had suffered severe acute respiratory syndrome (SARS-CoV-2) and recovered health workers.

First Published: